



JANUARY 27, 2022

**Medicinal Genomics Signs Diagnostech as its Distribution Partner
in Southern Africa**

Nascent Africa medical cannabis markets attract MGC's advanced testing technology

FOR IMMEDIATE RELEASE:

Beverly, MA. — Medicinal Genomics Corp. (MGC), a pioneer in harnessing genomics to improve agricultural productivity, safety, and transparency, today announced Diagnostech Pty Ltd., as its distribution partner in Southern Africa. Besides MGC, Diagnostech is the official sole distributor for Agilent Genomics and Diagnostic solutions, including Dako Pathology and Flow Cytometry Solutions, and a number of other life sciences firms on the continent. With business in 34 African countries, Diagnostech's mission is to expand the availability of equipment and services to meet the growing needs of science, research and medicinal cannabis in Africa.

"We are committed to being the continent's preferred genomics and pathology supplier, so we are always searching for the best quality products, and to bring the most innovative solutions to the African market. That's why Diagnostech is excited to partner with Medicinal Genomics, a world leader in cannabis genetics and microbial detection," said Monique McNab, Diagnostech Managing Director. "We look forward to making this growing and valuable technology available to our customers and we are excited to be playing a role in the development of the African cannabis industry.

South Africa joins a growing list of countries around the world who've legalized some form of cannabis production, research, and access. In 2019, the Southern African cannabis market generated an estimated \$1.4 billion in sales and is forecasted to grow at a modest 7% a year to be over \$2 billion by 2024. Business opportunities currently include cultivation and the importation of medical cannabis as well as over-the-counter CBD products. To date, the South African Health Products Regulatory Authority has received 20 applications for medical cannabis cultivation and was recently the first country on the continent to carve out a federally approved market for nonprescription CBD.

Despite the nascency of the country's market opportunities, its potential has attracted a notable amount of foreign investment. Three Canadian companies have established presences there: Canopy Growth has a medical cannabis subsidiary, Spectrum Therapeutics; Aphria has a joint venture with CannInvest Africa, and Alberta-based Aurora Cannabis has a supply agreement with Akula Trading.

"Cannabis is one of mankind's oldest natural resources and is now making its resurgence in Africa's legal markets," said Mike Catalano, Head of Medicinal Genomics' Genomic Services and International Sales. " Medicinal Genomics is proud to partner with Diagnostech to not only deliver



molecular tools that impact cannabis safety and consistency, but also screen for genetic traits that drive sustainable cultivation. Their local knowledge, commitment to quality and pursuit of novel technologies makes them the most forward-thinking company in the African market.”

The Covid-19 pandemic notwithstanding, MGC’s growth has tracked the acceptance and legalization of cannabis internationally by establishing partnerships with the leading biomedical and life science distributors in Northern Macedonia, Columbia, Argentina, Panama, Israel, Paraguay, Uruguay, Thailand and the Caribbean, and has added distribution agreements with global powerhouses Agilent, Eurofins, Hamilton and MGI.

About Diagnostech

Diagnostech, established in 2005, has been the sole distributor for Dako, in Southern Africa, with our territory now including more than 34 African countries. Agilent Technologies Inc. acquired Dako in 2012, and through this acquisition, Diagnostech became the official sole distributor for Agilent Genomics and Diagnostic solutions, including Dako Pathology and Flow Cytometry Solutions in South Africa. Diagnostech further expanded our portfolio to include product offerings from HistoCyte Laboratories, LGC Biosciences, ArcherDx and Diagenode. Recently, we have partnered with 10x Genomics, LevitasBio, Milestone Medical and Medicinal Genomics, to bring even more cutting-edge technology to our portfolio.

About Medicinal Genomics Corporation

Medicinal Genomics Corporation is a pioneer in leveraging genomics to build a stronger scientific foundation for cultivating medicinal plants and their extracts. The company’s unmatched expertise in genetic science helps cultivators, dispensaries and testing laboratories characterize, understand and ensure the safety, quality and consistency of their products so patients and consumers can have confidence in what they’re buying. To support their mission, Medicinal Genomics also produces CannMed, an annual gathering of cannabis leaders dedicated to the scientific advancement of the industry. For more information, please visit www.medicinalgenomics.com.

MGC media contact:

Frank Priscaro

frank.priscaro@medicinalgenomics.com

408.921.3110

###